Results 31 to 40 of about 41,247 (202)

Willingness to pay for an Ebola vaccine during the 2014–2016 ebola outbreak in West Africa: Results from a U.S. National sample

Human Vaccines & Immunotherapeutics, 2018
The 2014–2016 Ebola virus outbreak in West Africa led to advances in the development of vaccines against Ebola. This study examined factors associated with willingness to pay for an Ebola vaccine among a U.S.
Julia E. Painter, Michael E. von Fricken, Suyane Viana de O. Mesquita, Ralph J. DiClemente   +3 more
doaj   +1 more source

The Hajj 2019 Vaccine Requirements and Possible New Challenges [PDF]

, 2019
Each year millions of pilgrims perform the annual Hajj from more than 180 countries around the world. This is one of the largest mass gathering events and may result in the occurrence and spread of infectious diseases.
Al-Tawfiq, Jaffar A., Memish, Ziad A.
core   +1 more source

Ebola Model and Optimal Control with Vaccination Constraints

, 2017
The Ebola virus disease is a severe viral haemorrhagic fever syndrome caused by Ebola virus. This disease is transmitted by direct contact with the body fluids of an infected person and objects contaminated with virus or infected animals, with a death ...
Area, Ivan, Ndairou, Faical, Nieto, Juan J., Silva, Cristiana J., Torres, Delfim F. M.   +4 more
core   +1 more source

The Ebola virus: a review of progress and development in research

Asian Pacific Journal of Tropical Biomedicine, 2014
The Ebola virus was identified in the year 1976 and has caused periodic outbreaks in West African countries. The disease has a case fatality rate up to 90%.
Yitades Gebre, Teshome Gebre, Abena Peters   +2 more
doaj   +1 more source

Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries

Trials, 2021
Introduction The Ebola virus disease (EVD) outbreak in 2014–2016 in West Africa was the largest on record and provided an opportunity for large clinical trials and accelerated efforts to develop an effective and safe preventative vaccine.
Moses Badio, Edouard Lhomme, Mark Kieh, Abdoul Habib Beavogui, Stephen B. Kennedy, Seydou Doumbia, Bailah Leigh, Samba O. Sow, Alpha Diallo, Daniela Fusco, Matthew Kirchoff, Monique Termote, Renaud Vatrinet, Deborah Wentworth, Helène Esperou, H. Clifford Lane, Jerome Pierson, Deborah Watson-Jones, Céline Roy, Eric D’Ortenzio, Brian Greenwood, Genevieve Chêne, Laura Richert, James D. Neaton, Yazdan Yazdanpanah, the PREVAC study team   +25 more
doaj   +1 more source

A Novel Ebola Virus VP40 Matrix Protein-Based Screening for Identification of Novel Candidate Medical Countermeasures

Viruses, 2020
Filoviruses, such as Ebola virus and Marburg virus, are of significant human health concern. From 2013 to 2016, Ebola virus caused 11,323 fatalities in Western Africa.
Ryan P. Bennett, Courtney L. Finch, Elena N. Postnikova, Ryan A. Stewart, Yingyun Cai, Shuiqing Yu, Janie Liang, Julie Dyall, Jason D. Salter, Harold C. Smith, Jens H. Kuhn   +10 more
doaj   +1 more source

Treatment of Marburg and Ebola hemorrhagic fevers: A strategy for testing new drugs and vaccines under outbreak conditions. [PDF]

, 2008
The filoviruses, Marburg and Ebola, have the dubious distinction of being associated with some of the highest case-fatality rates of any known infectious disease-approaching 90% in many outbreaks.
A.G. Sprecher, Anon., Baize, Basler, Bausch, Bausch, Bausch, Bausch, Bausch, Bausch, Bausch, Bausch, Benjamin Jeffs, Bernard, Borchert, Bosio, Bosio, Boumandouki, Bray, Bray, Bray, Bray, Brummel-Ziedins, Bukreyev, Bwaka, CDC and WHO, Colebunders, Daddario-DiCaprio, Daniel G. Bausch, Dowell, Egbring, Emond, Enterlein, Feldmann, Formenty, Fourrier, Gear, Geisbert, Geisbert, Geisbert, Geisbert, Geisbert, Geisbert, Geisbert, Geisbert, Gibbs, Gupta, Hensley, Hensley, Hensley, Hewlett, Hewlett, Hoenen, Hotchkiss, Huggins, Jahrling, Jahrling, Jahrling, Jeffs, Johnson, Jones, Jones, Khan, Ksiazek, Kudoyarova-Zubavichene, Larkin, Leroy, Leroy, Mahanty, Mahanty, Martin, Martini, Martini, Monath, Mupapa, Mupapa, Nikiforov, Oswald, Parrino, Pattyn, Paul Boumandouki, Peters, Peterson, Peterson, Pourrut, Reid, Rivers, Roberts, Rollin, Sanchez, Schnittler, Schuler, Smith, Spurgers, Stille, Sullivan, Sullivan, Swanepoel, Takada, Todorovitch, Towner, Warfield, Warfield, Warfield, Wilson, Zaki   +105 more
core   +2 more sources

Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates

Human Vaccines & Immunotherapeutics, 2019
The filoviruses Ebola virus and Marburg virus are among the most dangerous pathogens in the world. Both viruses cause viral hemorrhagic fever, with case fatality rates of up to 90%. Historically, filovirus outbreaks had been relatively small, with only a
John J. Suschak, Connie S. Schmaljohn
doaj   +1 more source

Ebola Vaccine Trials [PDF]

, 2017
The Ebola epidemic that broke out in West Africa towards the end of 2013 had been brought under reasonable control by 2015. The epidemic had severely affected three countries. This case study is about a phase I/II clinical trial (testing for safety and immunogenicity) of a candidate Ebola virus vaccine in 2015 in a sub-Saharan African country which had
Godfrey B. Tangwa, Katharine Browne, Doris Schroeder   +2 more
openaire   +1 more source

Racing against COVID-19: a vaccines strategy for Europe. Bruegel Policy Contribution Issue n˚7 | April 2020 [PDF]

, 2020
The fast development of vaccines is an essential part of the long-term solution to COVID-19, but vaccine development has high costs and carries the risk of high failure rates.
Veugelers, Reinhilde, Zachmann, Georg.
core   +1 more source